Add a New Bulls Reason

Company: Schering-Plough (SGP)
Current price:
Headline: (100 character max)
Analysis:
Cancel
88%
agree
9 votes

edit Zetia and Vytorin are hugely successful cholesterol drugs

Zetia and Vytorin are hugely successful cholesterol drugs with novel action mechanisms and sales approaching $4 billion in 2006. Recent Japanese approval of the treatments means increased sales, and with no additional testing and trials necessary, a high proportion of sales is profit.

(100 character max) Cancel
50%
agree
2 votes

edit Schering-Plough working with JNJ on successor to Remicade

Schering-Plough is working with Johnson & Johnson on a possible successor to its most successful drug, Remicade. The autoimmune treatment market is growing, and so any advances in this field would be very profitable.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki